title: Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.
abstract: BACKGROUND
  Paraneoplastic neurologic syndrome (PNS) represents the remote effects of cancer on the nervous system. Diagnostic criteria for the syndrome were published by the PNS Euronetwork and form the basis of a database to collect standardized clinical data from patients with PNS.
  
  
  OBJECTIVE
  To analyze various types of PNS, frequent tumor and antibody associations, clinical characteristics of individual syndromes, and possible therapeutic and prognostic strategies.
  
  
  METHODS
  Prospective case series and database study.
  
  
  METHODS
  Twenty European centers. Patients Patients were recruited from January 1, 2000, to December 31, 2008.
  
  
  METHODS
  Based on diagnostic criteria published by the PNS Euronetwork consortium, clinical characteristics of classic PNS and several other less well-characterized syndromes associated with cancer were assessed.
  
  
  RESULTS
  Data from 979 patients were analyzed, representing the largest PNS investigation to date. The findings elucidate the clinical evolution of paraneoplastic cerebellar syndrome according to the onconeural antibodies present, the heterogeneity and prognosis of dysautonomic disorders, and the clinical variability of paraneoplastic limbic encephalitis.
  
  
  CONCLUSIONS
  The study results confirm that PNS influences oncologic patient survival. Tumors are the main cause of death, but some types of PNS (such as dysautonomia) have a poorer prognosis than malignant neoplasms.
authors.affiliation: Department of Neurology, Ospedale Ca'Foncello, Azienda Unità Locale Socio-Sanitaria 9 Treviso, Piazza Ospedale 1, 31100 Treviso, Italy. bruno.giometto@unipd.it
authors.forename: Bruno
authors.initials: B
authors.lastname: Giometto
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Grisold
authors.forename: Roberta
authors.initials: R
authors.lastname: Vitaliani
authors.forename: Francesc
authors.initials: F
authors.lastname: Graus
authors.forename: Jérôme
authors.initials: J
authors.lastname: Honnorat
authors.forename: Guido
authors.initials: G
authors.lastname: Bertolini
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000906:Antibodies / Q000276:immunology; D015153:Blotting, Western; D001921:Brain / Q000276:immunology; D002423:Cause of Death; D016208:Databases, Factual; D018450:Disease Progression; D005060:Europe; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D009474:Neurons / Q000276:immunology; D020361:Paraneoplastic Syndromes, Nervous System / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D010951:Plasma Exchange; D011379:Prognosis; D011446:Prospective Studies; D011863:Radioimmunoassay
chemical_list: D000305:Adrenal Cortex Hormones; D000906:Antibodies; D007136:Immunoglobulins